TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Go back to TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)| (NASDAQ: IONS) | Delayed: 44.44 -2.31 (4.94%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.75 | 52 Week High | $62.68 | |||
| Open | $46.75 | 52 Week Low | $19.59 | |||
| Day High | $46.75 | P/E | N/A | |||
| Day Low | $44.27 | EPS | $0.00 | |||
| Volume | 7,369,252 | |||||
